Lonvosi delivered strong Phase 3 efficacy with launch preparation underway, while Nexi carries allele-linked liver safety and clinical execution risks.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-08-06 |
| Length | 42 minutes |
| EPS | $-0.80 |
| EPS consensus | $-0.80 |
| Revenue | $7.7M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q4 FY25
Read the full Q2 FY26 earnings call transcript
All NTLA earnings · Back to NTLA overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.